World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa.
This World Federation of Societies of Biological Psychiatry (WFSBP) consensus paper aims to summarise and evaluate the published study results on objectively measurable biological markers associated with anorexia nervosa (AN).
The relevant literature was reviewed by the WFSBP Task Forces on Eating Disorders and on Biological Markers, and a consensus regarding the significance of the published evidence was reached.
Candidate biological markers that have been associated with AN include clinical (e.g. body weight), molecular (e.g. genetic, epigenetic, hormonal, immunological, metabolomic), cellular (e.g. leukocytes), neuroimaging (e.g. structure, function, connectivity), digital, cardiac and neurophysiological parameters. Some clinical and laboratory parameters are risk markers in clinical practice. Biological markers have pathophysiological relevance in understanding the biological and metabolic pathophysiology of AN and its physical health consequences. Few studies have examined pharmacogenetics or therapeutic drug monitoring as tools to monitor and guide the treatment of AN.
Biological markers will hopefully soon enable clinicians to intervene earlier in a more targeted manner to mitigate treatment resistance. However, the current scientific basis for most biological markers are group comparisons only. Studies on sensitivity, specificity and the prognostic value of these markers are lacking.
The relevant literature was reviewed by the WFSBP Task Forces on Eating Disorders and on Biological Markers, and a consensus regarding the significance of the published evidence was reached.
Candidate biological markers that have been associated with AN include clinical (e.g. body weight), molecular (e.g. genetic, epigenetic, hormonal, immunological, metabolomic), cellular (e.g. leukocytes), neuroimaging (e.g. structure, function, connectivity), digital, cardiac and neurophysiological parameters. Some clinical and laboratory parameters are risk markers in clinical practice. Biological markers have pathophysiological relevance in understanding the biological and metabolic pathophysiology of AN and its physical health consequences. Few studies have examined pharmacogenetics or therapeutic drug monitoring as tools to monitor and guide the treatment of AN.
Biological markers will hopefully soon enable clinicians to intervene earlier in a more targeted manner to mitigate treatment resistance. However, the current scientific basis for most biological markers are group comparisons only. Studies on sensitivity, specificity and the prognostic value of these markers are lacking.
Authors
Himmerich Himmerich, Keeler Keeler, King King, Ehrlich Ehrlich, Kaufmann Kaufmann, Bulik Bulik, Cohen-Woods Cohen-Woods, Wade Wade, Steiger Steiger, Booij Booij, Monteleone Monteleone, Cascino Cascino, Monteleone Monteleone, Cuntz Cuntz, Voderholzer Voderholzer, Tessema Tessema, Lewis Lewis, Sjögren Sjögren, Hebebrand Hebebrand, Seitz Seitz, Tyszkiewicz-Nwafor Tyszkiewicz-Nwafor, Karpenko Karpenko, Mutwalli Mutwalli, Fetissov Fetissov, Mack Mack, Dhopatkar Dhopatkar, Mörkl Mörkl, Kan Kan, Uribe Uribe, Yoshiuchi Yoshiuchi, Abuobeid Abuobeid, Kapogiannis Kapogiannis, Stein Stein, Bektas Bektas, Müller Müller, Gorwood Gorwood, Duriez Duriez, Montcel Montcel, Paszyńska Paszyńska, McElroy McElroy, Wranik Wranik, Fernandez-Aranda Fernandez-Aranda, Mehler Mehler, Papežová Papežová, Roubalová Roubalová, Procházková Procházková, Morris Morris, Lewczuk Lewczuk, Hiemke Hiemke, Berk Berk, Karwautz Karwautz, Treasure Treasure, Kasper Kasper, ,
View on Pubmed